Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

Kidney International

Volumn 79, Issue SUPPL. 120, 2011, Pages

  List, James F ^a   Whaley, Jean M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

diabetes mellitus, type 2; glucosuria; SGLT2 inhibitors; sodium glucose transport proteins

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTIDIURETIC AGENT; ANTIHYPERTENSIVE AGENT; ASP 1941; BI 10773; CANAGLIFLOZIN; DAPAGLIFLOZIN; FUROSEMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LX 4211; METFORMIN; ORAL ANTIDIABETIC AGENT; PHLORIZIN; PLACEBO; REMOGLIFLOZIN; SERGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ALBUMINURIA; ANTIDIURESIS; B LYMPHOCYTE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIABETES MELLITUS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LYMPHOCYTE ACTIVATION; MICROANGIOPATHY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; UREMIA; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY PROXIMAL TUBULE; METABOLISM; PANCREAS ISLET BETA CELL;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; KIDNEY TUBULES, PROXIMAL; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 79952221451     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.512     Document Type: Review

References (44)

1. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43. (Pubitemid 46046470)
2. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008; 14: 782-790.
3. Pajor AM, Randolph KM, Kerner SA et al. Inhibitor binding in the human renal low-and high-affinity Na+/glucose cotransporters. J Pharmacol Exp Ther 2008; 324: 985-991. (Pubitemid 351397847)
4. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280: F10-F18.
5. Fujimori Y, Katsuno K, Nakashima I et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-276.
6. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149. (Pubitemid 351480378)
7. Fujimori Y, Katsuno K, Ojima K et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009; 609: 148-154.
8. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
9. Liang Y, Arakawa K, Martin T et al. JNJ-28431754/TA-7284, an SGLT inhibitor, lowers blood glucose and reduces body weight in obese and type 2 diabetic animal models. In American Diabetes Association 69th Scientific Sessions (vol Poster), New Orleans, Louisiana 2009, pp 534-P.
10. Rossetti L, Smith D, Shulman GI et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-1515. (Pubitemid 17099657)
11. Blondel O, Bailbe D, Portha B. Insulin resistance in rats with non-insulindependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism 1990; 39: 787-793. (Pubitemid 20250989)
12. Kahn BB, Shulman GI, DeFronzo RA et al. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991; 87: 561-570.
13. Kim YW, Kim JY, Lee SK. Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats. J Korean Med Sci 1995; 10: 24-30.
14. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005; 47: 201-210. (Pubitemid 43471964)
15. Simonson GD, Kendall DM. Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus. Coron Artery Dis 2005; 16: 465-472. (Pubitemid 44365932)
16. Katsuno K, Fujimori Y, Ishikawa-Takemura Y et al. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol 2009; 618: 98-104.
17. Macdonald R, Westgate L, Poucher SM et al. The SGLT2 inhibitor dapagliflozin prevents the loss of pancreatic function in the high fat fed female (HFFF) ZDF rat. Diabetes 2009; 58(Suppl 1): A380.
18. Ueta K, Ishihara T, Matsumoto Y et al. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005; 76: 2655-2668. (Pubitemid 40404055)
19. Arakawa K, Ishihara T, Oku A et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001; 132: 578-586. (Pubitemid 32142370)
20. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
21. Shi ZQ, Rastogi KS, Lekas M et al. Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats. Endocrinology 1996; 137: 3193-3199. (Pubitemid 26250163)
22. Rastogi KS, Cooper RL, Shi ZQ et al. Quantitative measurement of islet glucagon response to hypoglycemia by confocal fluorescence imaging in diabetic rats: effects of phlorizin treatment. Endocrine 1997; 7: 367-375. (Pubitemid 28223945)
23. Vallon V, Richter K, Blantz RC et al. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 1999; 10: 2569-2576.
24. Thomson SC, Miracle CM, Rieg T et al. Chronic SGLT2 blockade reduces proximal reabsorption and normalizes state of tubuloglomerular feedback activation in hyperfiltering diabetic rats. J Am Soc Nephrol 2009; 20: 734A.
25. Henderson RP, Covinsky JO. Effect of protein on renal function and drug disposition. Drug Intell Clin Pharm 1986; 20: 842-844. (Pubitemid 16010351)
26. Devenny J, Harvey S, Rooney S et al. The effect of dapagliflozin, a highly selective SGLT-2 inhibitor on body weight in diet-induced obese rats. Obesity 2007; 15(Suppl): A121.
27. Katsuno K, Fujimori Y, Takemura Y et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320: 323-330. (Pubitemid 46025747)
28. Akiyama T, Weinglass A, Zhou Y et al. The sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, displays anti-diabetic activity in db/db mice. In ENDO 2009 The 91st Annual Meeting (vol Poster), Washington, DC 2009, abstract no. P2-429.
29. Kapur A, O'Connor-Semmes RL, Hussey EK et al. First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects with type 2 diabetes mellitus (T2DM). Diabetes 2009; 58(Suppl 1): 509-P.
30. Komoroski B, Vachharajani N, Feng Y et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519.
31. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526.
32. Hussey EK, Clark RV, Amin DM et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics lf single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus. Diabetes 2007; 56(Suppl 1): 189-OR.
33. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-109.
34. Rahmoune H, Thompson PW, Ward JM et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-3434. (Pubitemid 43334332)
35. Vestri S, Okamoto MM, de Freitas HS et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001; 182: 105-112. (Pubitemid 32641748)
36. Albertoni Borghese MF, Majowicz MP, Ortiz MC et al. Expression and activity of SGLT2 in diabetes induced by streptozotocin: relationship with the lipid environment. Nephron Physiol 2009; 112: p45-p52.
37. Dobbins RL, Kapur A, Kapitza C et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus (T2DM) patients. Diabetes 2009; 58(Suppl 1): 573-P.
38. List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
39. Wilding JP, Norwood P, T'Joen C et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662.
40. Bailey CJ, Gross JL, Pieters A et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
41. Bailey CJ, Gross JL, Bastone L et al. Dapagliflozin as an add-on to metformin lowers hyperglycaemia in type 2 diabetes patients inadequately controlled with metformin alone. Diabetologia 2009; 52 (Suppl 1): S76.
42. Leslie B, Tang W, List JF. Renal effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (BMS-512148) in patients with type 2 diabetes mellitus. J Am Soc Nephrol 2008; 19: 341A.
43. Ferrannini E, Ramos SJ, Salsali A et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.
44. Nunoi K, Yasuda K, Adachi T et al. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 2002; 29: 386-390. (Pubitemid 34535357)